Imatinib for chronic myeloid leukaemia: Further assessment required

Prescrire International

Volumn 12, Issue 64, 2003, Pages 49-52

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CYTARABINE; HYDROXYUREA; IMATINIB; KETOCONAZOLE; PARACETAMOL; PROTEIN TYROSINE KINASE; SIMVASTATIN; WARFARIN; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTHRALGIA; ARTICLE; BLAST CELL CRISIS; BLOOD CELL; BLOOD CELL COUNT; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CHRONICITY; CLINICAL PRACTICE; CLINICAL TRIAL; CYTOGENETICS; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC CODE; HUMAN; LIVER TOXICITY; MYALGIA; NAUSEA; NEPHROTOXICITY; ONCOGENE; PHILADELPHIA 1 CHROMOSOME; SIDE EFFECT; TREATMENT FAILURE; VOMITING; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG SCREENING; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG EVALUATION; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS;

EID: 0345672454     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. The European Agency for the Evaluation of Medicinal Products - Committee for Proprietary Medicinal Products - European Public Assessment Report "Glivec°" London 15 August 2002: 101 pages.
2. Food and Drug Administration - Center for Drug Evaluation and Research "Application number: NDA-21-335 - Medical review" 8 May 2001: 130 pages.
3. Novartis "Glivec° (imatinib mesilate) ST1571/CGP57148B - Expert Report on clinical documentation" 21 February 2001: 38 pages.
4. Kantarjian H et al. "Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia" N Engl J Med 2002; 346 (9): 645-652.
5. Druker BJ "STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomized study". Website http://www.asco.org consulted on 23 May 2002.
6. Shah NP et al. "Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia" Cancer Cell 2002; 2: 117.
7. Talpaz M et al. "Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study" Blood 2002; 99 (6): 1928-1937.
8. Sawyers CL et al. "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study" Blood 2002; 99 (10): 3530-3539.
9. Kantarjian HM et al. "Clinical course and therapy of chronic myelogenous leukemia with interferon-alfa and chemotherapy" Hematol Oncol Clin North Am 1998; 12 (1): 31-80.
10. Bowling A "Cancers". In: "Measuring disease" Open University Press, Buckingham 1995: 20-60.